Cencora stock: 9.78 percent below its 52-week high, Cencora stock costs EUR 304.20

Published on 10/22/2026 at 15:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results come November 4 with USD 17.90 minimum adjusted EPS guidance. Cencora stock costs EUR 304.20 at Lang & Schwarz on October 22, 2026.

Price and dates at a glance

Cencora's fiscal third-quarter revenue reached USD 84.80 billion in the period ended June 30, 2026.
Adjusted fiscal 2026 earnings guidance starts at USD 17.90 per share.
Cencora stock costs EUR 304.20 at Lang & Schwarz on October 22, 2026 at 3:37 p.m. CEST.
Fiscal fourth-quarter results are scheduled for November 4, 2026.

Luftbild eines modernen Pharma-Lagerzentrums mit Lieferfahrzeugen und Verladedocks — Cencora Inc. betreibt US15135B1017 ein großes Pharmadistributionszentrum mit Lastwagen Gabelstaplern und täglicher Medikamentenlogistik, Illustration mit AI erstellt.

Cencora stock is 9.78 percent below its NYSE 52-week high of USD 377.54, while the company prepares to report fiscal fourth-quarter results on November 4, 2026. Yahoo Finance reported that adjusted fiscal 2026 earnings guidance stood at USD 17.75 to USD 17.95 per share after the third quarter. At Lang & Schwarz, the stock was trading at EUR 304.20 on October 22, 2026 at 3:37 p.m. CEST.

Revenue reached USD 84.80 billion

For the fiscal third quarter ended June 30, 2026, Cencora reported revenue of USD 84.80 billion, up 5.00 percent from the prior-year quarter. Adjusted operating income increased 17.00 percent to USD 1.20 billion, while adjusted earnings per share grew 12.00 percent. These figures give the November report a demanding comparison base.

The stock stays below USD 377.54

The NYSE quote was USD 340.61 on October 22, 2026 at 9:49 a.m. ET, with a 52-week range of USD 244.82 to USD 377.54. The price was 9.78 percent below the high and 39.13 percent above the low. Cencora's market capitalization was USD 65.0 billion, and its price-to-earnings ratio was 25.31.

What does the valuation show?

The valuation sits between two large pharmaceutical distributors. On October 22, 2026, Cencora's NYSE change was 0.05 percent, its price-to-earnings ratio was 25.31, and its market capitalization was USD 65.0 billion. Cardinal Health's corresponding figures were minus 0.26 percent, 35.59, and USD 59.5 billion, while McKesson posted minus 0.03 percent, 27.14, and USD 118.4 billion.

November 4 is the next date

Cencora scheduled its fiscal fourth-quarter 2026 results for November 4, 2026, before trading on the New York Stock Exchange, with the conference call set for 8:30 a.m. ET. The company also said its adjusted fiscal 2026 earnings guidance now starts at USD 17.90 per share. That date should bring the next update on fiscal 2027 expectations.

Price position and reporting date

Cencora's combination of USD 84.80 billion in quarterly revenue, a 25.31 price-to-earnings ratio, and a USD 65.0 billion market value places the stock below its annual high while the next earnings date approaches. The November release will provide the next reported comparison for the pharmaceutical distributor.

The further course of trading is shown by the continuously updated real-time quote of Cencora stock.